Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).

Metenova is a leading innovator and manufacturer of magnetic mixers for pharmaceutical and biotechnology applications. The company is headquartered in Mölndal, Gothenburg.

The acquisition of Metenova strengthens Repligen's fluid management portfolio, with a product line that expands on the success of Repligen's systems and fluid management assemblies.

Vinge's team mainly consisted of Jonas Bergström, Johanna Wiberg, Viktor Lennartsson, Robin Sultani (M&A), Sam Seddigh, Hanna Marberg (employment), David Olander (competition), Mathilda Persson, Mika Jordan, Arthur Kinski, Mario Saad (commercial agreements), Christoffer Nordin (Life Science/Regulatory), Lisa Hörnqvist (IT and GDPR), Stojan Arnerstål, Axel Lennartsson, Johan Gavelin (IP), Kristoffer Larson (real property), Mia Falk (compliance), Anders Leissner (sanctions/export control) and Cecilia Loctander (project assistant).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025